ZYME Stock Analysis: Buy, Sell, or Hold?
ZYME - Zymeworks Inc.
$28.67
2.10 (7.90%)
▲
5d:
+14.13%
30d:
+24.01%
90d:
+14.18%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ZYME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ZYME is 11.4% above its trading range ($25.73). Market expects -25.6% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ZYME is 11.4% above its trading range ($25.73). Market expects -25.6% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.57
Based on 4.5% avg growth
INTRINSIC VALUE TODAY
$22.71
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZYME is currently trading at $28.67, which is considered extended relative to its 30-day fair value range of $22.51 to $25.73. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.4) compared to its historical average (59.1). Remarkably, the market is currently pricing in an annual earnings decline of 25.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZYME is in a downtrend. The price is approaching resistance at $28.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: ZYME scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.33 (+40.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZYME is in a downtrend. The price is approaching resistance at $28.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: ZYME scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.33 (+40.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$22.51 -
$25.73
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
38.5%
Protect Your Profits
ZYME is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+11.4% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.9%)
- BULLISH: Trading 40.7% below Wall St target ($40.33)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$22.51 -
$25.73
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.11
(7.3%)
Support & Resistance Levels
Support Level
$23.47
Resistance Level
$28.74
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.36
Wall Street Target
$40.33
(+40.7%)
Revenue Growth (YoY)
-90.6%
Valuation Discount vs History
-25.6% cheaper
PE vs Historical
24.4 vs 59.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-25.6%
(market-implied from PE analysis)
1-Year Target
$25.80
(-10%)
2-Year Target
$23.22
(-19%)
3-Year Target
$20.90
(-27%)
3-Yr Target (if PE normalizes)
(PE: 24→59)
$50.70
(+77%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.4, Growth: 4.9%)
$33.09
(+15%)
Base:
(SPY PE: 20.1, Growth: 4.9%)
$27.26
(-5%)
Bear:
(PE: 17.1, Growth: 4.9%)
$23.17
(-19%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.4 to 59.1
Stabilization Target:
$69.55
(+142.6%)
PE Expansion Potential:
+142.6%
Share & Embed Analysis
Last updated: August 23, 2026 10:32 PM ET
Data refreshes hourly during market hours. Next update: 11:32 PM
Data refreshes hourly during market hours. Next update: 11:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 52 HOLD |
Advanced ZYME Option Strategies
Professional options setups generated by AI based on today's ZYME price and gamma walls.
